Table 1: Baseline characteristics of the study cohort.

CharacteristicGroup 1Group 2
HCV patients ( )HBV patients ( )
(%) (%)

Sex— (%)
 Male74 (63.8)34 (53.1)
 Female42 (36.2)30 (46.9)
Age (years)54 ± 2.353 ± 2.6
Racecaucasiancaucasian
Body-mass index (Kg/m2)26.5 ± 1.027.6 ± 1.2
Blood pressure (sys/dia)—mmHg128 ± 0.8/84 ± 0.3132 ± 1.1/81 ± 0.7
Weight (Kg)68.5 ± 1.371.2 ± 0.6
AST—IU/L (n.v. 8–18)63 ± 0.773 ± 0.6
ALT—IU/L (n.v. 8–18)75 ± 1.281 ± 0.8
GT—IU/L (n.v. 2–30)34 ± 1.432 ± 1.1
Cholinesterase—IU/L (n.v. 4900–11900)5982 ± 102.55878 ± 190.3
Alkaline Phosphatase—IU/L (n.v. 35–100)86 ± 0.889 ± 1.0
Total bilirubin—mg/dL (n.v. 0.2–1.2)1.06 ± 0.51.07 ± 0.3
Conjugated bilirubin—mg/dL (n.v. 0.0–0.4)0.16 ± 0. 20.14 ± 0.1
Viremia
Mean—log IU/mL6.40 ± 0.866.31 ± 0.92
Genotype1b (100)D39 (81.2)
A 4 (8.3)
D + A2 (4.2)
D + F2 (4.2)
D + F + A1 (2.1)
Fasting glucose—mg/dL (n.v. 74–106)86 ± 1.3 79 ± 1.5
Serum urea—mg/dL (n.v. 6–40)42 ± 2.139 ± 2.3
Serum creatinin—mg/dL (n.v. 0.7–1.3)0.7 ± 0.10.6 ± 0.2
Serum proteins—mg/dL (n.v. 6–8)7.1 ± 0.67.4 ± 0.3
Fibrinogen—mg/dL (n.v. 200–400)325 ± 10.3316 ± 11.5
Prostatic Specific Antigen—ng/mL (n.v. < 0.4)1.3 ± 0.71.8 ± 0.5
ANA, AMA, SMA, LKM1NegativeNegative
C3-C4—mg/dL91 ± 1.689 ± 1.9
PLTs count-cell/mm3218 ± 19 × 103216 ± 21 × 103
Prothrombin time-sec10 ± 0.39.8 ± 0.2
Prothrombin-%112 ± 0.9104 ± 1.3
INR—% (n.v. 0.9–1.2)1.2 ± 0.21.1 ± 0.6
Child-Pugh score≤5≤5
CA19.9—IU/mL (v.n. < 39)76.8 ± 42.378.8 ± 41.6

Values are expressed as the mean ± SD. The body-mass index is the weight in kilograms divided by the square of the height in meters.
Viremia stands for quantitative HCV-RNA in Group 1 and HBV-DNA in Group 2 respectively.